Results 251 to 260 of about 120,068 (304)

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

open access: yesArthritis &Rheumatology, Accepted Article.
‐
Kerem Abacar   +5 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

BLIMP-1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses. [PDF]

open access: yesImmunol Cell Biol
Phetsouphanh C   +10 more
europepmc   +1 more source

Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity. [PDF]

open access: yesCancer Res
Bockman A   +8 more
europepmc   +1 more source

HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma. [PDF]

open access: yesMol Biomed
Yang F   +10 more
europepmc   +1 more source

Tregs in transplantation tolerance: role and therapeutic potential [PDF]

open access: yesFrontiers in Transplantation, 2023
CD4+ Foxp3+ regulatory T cells (Tregs) are indispensable for preventing autoimmunity, and they play a role in cancer and transplantation settings by restraining immune responses.
Maria-Luisa Alegre   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy